- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06103864
Een fase III-onderzoek naar Dato-DXd met of zonder Durvalumab vergeleken met chemotherapie naar keuze van de onderzoeker in combinatie met Pembrolizumab bij patiënten met PD-L1-positieve, lokaal recidiverende inoperabele of gemetastaseerde triple-negatieve borstkanker
Een fase III, open-label, gerandomiseerde studie van Datopotamab Deruxtecan (Dato-DXd) met of zonder Durvalumab vergeleken met chemotherapie naar keuze van de onderzoeker (Paclitaxel, Nab-paclitaxel of Gemcitabine + Carboplatine) in combinatie met Pembrolizumab bij patiënten met PD-L1-positief Lokaal recidiverende, inoperabele of gemetastaseerde drievoudige negatieve borstkanker (TROPION-Breast05)
This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizumab in participants with PD-L1 positive locally recurrent inoperable or metastatic TNBC.
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
The primary objective of the study is to demonstrate superiority of Dato-DXd + durvalumab relative to ICC + pembrolizumab by assessment of PFS as assessed by BICR in participants with PD-L1 positive locally recurrent inoperable or metastatic TNBC.
The study will be stratified based on geographic location (US/Canada/Europe vs. Dato-DXd monotherapy enrolling countries vs. rest of world), disease-free interval (DFI) history (de novo vs. prior DFI 6 to 12 months vs. prior DFI > 12 months), and prior PD-1/PD-L1 treatment for early stage TNBC (yes vs. no).
This study aims to see if Dato-DXd with durvalumab allows patients to live longer without their breast cancer getting worse, or simply to live longer, compared to patients receiving standard of care chemotherapy and pembrolizumab. This study is also looking to see how the treatment and the breast cancer affects patients' quality of life.
Studietype
Inschrijving (Geschat)
Fase
- Fase 3
Contacten en locaties
Studiecontact
- Naam: AstraZeneca Clinical Study Information Center
- Telefoonnummer: 1-877-240-9479
- E-mail: information.center@astrazeneca.com
Studie Contact Back-up
- Naam: AstraZeneca Breast Cancer Study Locator Service
- Telefoonnummer: +1-877-400-4656
- E-mail: az-bcsl@careboxhealth.com
Studie Locaties
-
-
-
CABA, Argentinië, 1425
- Werving
- Research Site
-
CABA, Argentinië, 1414
- Werving
- Research Site
-
CABA, Argentinië, C1425
- Ingetrokken
- Research Site
-
CABA, Argentinië, C1113AAE
- Werving
- Research Site
-
Ciudad Autónoma Buenos Aires, Argentinië, C1430EFA
- Werving
- Research Site
-
Ciudad de Buenos Aires, Argentinië, C1015ABO
- Werving
- Research Site
-
Rosario, Argentinië, 2000
- Werving
- Research Site
-
San Nicolás de los Arroyos, Argentinië, B2900
- Ingetrokken
- Research Site
-
-
-
-
-
Camperdown, Australië, 2050
- Werving
- Research Site
-
Darlinghurst, Australië, 2010
- Voltooid
- Research Site
-
Heidelberg, Australië, 3084
- Voltooid
- Research Site
-
Melbourne, Australië, 3000
- Werving
- Research Site
-
Nedlands, Australië, 6009
- Werving
- Research Site
-
Waratah, Australië, 2298
- Ingetrokken
- Research Site
-
-
-
-
-
Barretos, Brazilië, 14784-400
- Werving
- Research Site
-
Curitiba, Brazilië, 80730-150
- Werving
- Research Site
-
Florianópolis, Brazilië, 88034-000
- Werving
- Research Site
-
Goiânia, Brazilië, 74000-000
- Werving
- Research Site
-
Itajaí, Brazilië, 88301-220
- Werving
- Research Site
-
Porto Alegre, Brazilië, 90035-003
- Werving
- Research Site
-
Recife, Brazilië, 52010-075
- Werving
- Research Site
-
São Paulo, Brazilië, 01246-000
- Werving
- Research Site
-
São Paulo, Brazilië, 01317-001
- Werving
- Research Site
-
Teresina, Brazilië, 64049-200
- Werving
- Research Site
-
-
-
-
Ontario
-
Barrie, Ontario, Canada, L4M 6M2
- Werving
- Research Site
-
Hamilton, Ontario, Canada, L8V 5C2
- Werving
- Research Site
-
Toronto, Ontario, Canada, M5G 2M9
- Werving
- Research Site
-
-
Quebec
-
Greenfield Park, Quebec, Canada, J4V 2H1
- Werving
- Research Site
-
Montreal, Quebec, Canada, H4A 3J1
- Werving
- Research Site
-
Montreal, Quebec, Canada, H2X 0A9
- Werving
- Research Site
-
Québec, Quebec, Canada, G1S 4L8
- Werving
- Research Site
-
-
Saskatchewan
-
Regina, Saskatchewan, Canada, S4T 7T1
- Werving
- Research Site
-
Saskatoon, Saskatchewan, Canada, S7N 4H4
- Werving
- Research Site
-
-
-
-
-
Anyang, China, 455000
- Werving
- Research Site
-
Beijing, China, 100044
- Werving
- Research Site
-
Beijing, China, 100142
- Werving
- Research Site
-
Bengbu, China, 233004
- Werving
- Research Site
-
Changchun, China, 130021
- Werving
- Research Site
-
Changsha, China, 410008
- Werving
- Research Site
-
Changsha, China, 410013
- Werving
- Research Site
-
Chengdu, China, 610000
- Werving
- Research Site
-
Chengdu, China, 610041
- Werving
- Research Site
-
Chongqing, China, 400030
- Ingetrokken
- Research Site
-
Fuzhou, China, 350014
- Werving
- Research Site
-
Guangzhou, China, 510120
- Werving
- Research Site
-
Guangzhou, China, 510060
- Werving
- Research Site
-
Guangzhou, China, 510700
- Werving
- Research Site
-
Hangzhou, China, 310009
- Werving
- Research Site
-
Hangzhou, China, 310022
- Werving
- Research Site
-
Hangzhou, China, 310016
- Werving
- Research Site
-
Harbin, China, 150081
- Werving
- Research Site
-
Hefei, China, 230031
- Werving
- Research Site
-
Jinan, China, 250021
- Actief, niet wervend
- Research Site
-
Meizhou, China, 514031
- Werving
- Research Site
-
Nanchang, China, 330009
- Werving
- Research Site
-
Nanjing, China, 210009
- Werving
- Research Site
-
Nanjing, China, 2100008
- Werving
- Research Site
-
Nanning, China, 530021
- Werving
- Research Site
-
Shandong, China
- Werving
- Research Site
-
Shanghai, China, 200025
- Werving
- Research Site
-
Shanghai, China, 200080
- Voltooid
- Research Site
-
Shenyang, China, 110004
- Werving
- Research Site
-
Taiyuan, China, 030000
- Werving
- Research Site
-
Tianjin, China, 300000
- Werving
- Research Site
-
Wenzhou, China, 325000
- Werving
- Research Site
-
Wuhan, China, 430022
- Werving
- Research Site
-
Wuhan, China, 430079
- Werving
- Research Site
-
Xi'an, China, 710061
- Werving
- Research Site
-
Xiamen, China, 361003
- Werving
- Research Site
-
Xintai, China, 54031
- Werving
- Research Site
-
Xuzhou, China, 221009
- Werving
- Research Site
-
Zhanjiang, China, 524003
- Werving
- Research Site
-
Zhengzhou, China, 450008
- Werving
- Research Site
-
Zhengzhou, China, 450052
- Werving
- Research Site
-
-
-
-
-
Düsseldorf, Duitsland, 40479
- Ingetrokken
- Research Site
-
Essen, Duitsland, 45136
- Ingetrokken
- Research Site
-
Georgsmarienhütte, Duitsland, 49124
- Ingetrokken
- Research Site
-
Hamburg, Duitsland, 20357
- Ingetrokken
- Research Site
-
Hanover, Duitsland, 30625
- Ingetrokken
- Research Site
-
Heidelberg, Duitsland, 69120
- Ingetrokken
- Research Site
-
Heilbronn, Duitsland, 74078
- Ingetrokken
- Research Site
-
Leipzig, Duitsland, 04103
- Ingetrokken
- Research Site
-
-
-
-
-
Bacolod, Filippijnen, 6100
- Werving
- Research Site
-
Cebu City, Filippijnen, 6000
- Werving
- Research Site
-
City of Muntinlupa, Filippijnen, 1780
- Werving
- Research Site
-
Manila, Filippijnen, 1000
- Werving
- Research Site
-
Quezon City, Filippijnen, 1112
- Werving
- Research Site
-
San Juan City, Filippijnen, 1502
- Werving
- Research Site
-
-
-
-
-
Lille, Frankrijk, 59000
- Werving
- Research Site
-
Lyon, Frankrijk, 69373
- Werving
- Research Site
-
Montpellier, Frankrijk, 34298
- Werving
- Research Site
-
Paris, Frankrijk, 75020
- Werving
- Research Site
-
Saint-Herblain, Frankrijk, 44805
- Werving
- Research Site
-
Toulouse, Frankrijk, 31059
- Werving
- Research Site
-
Vandœuvre-lès-Nancy, Frankrijk, 54511
- Werving
- Research Site
-
Villejuif, Frankrijk, 94800
- Werving
- Research Site
-
-
-
-
-
Hong Kong, Hongkong, 999077
- Werving
- Research Site
-
-
-
-
-
Calicut, Indië, 673601
- Ingetrokken
- Research Site
-
Chennai, Indië, 600031
- Werving
- Research Site
-
Jaipur, Indië, 302004
- Ingetrokken
- Research Site
-
Kochi, Indië, 682027
- Ingetrokken
- Research Site
-
Kolkata, Indië, 700160
- Ingetrokken
- Research Site
-
Kottayam, Indië, 686008
- Werving
- Research Site
-
Marg Jaipur, Indië, 302004
- Werving
- Research Site
-
Mohali, Indië, 160055
- Werving
- Research Site
-
Mysuru, Indië, 570017
- Werving
- Research Site
-
Nagpur, Indië, 440001
- Werving
- Research Site
-
Nashik, Indië, 422009
- Werving
- Research Site
-
New Delhi, Indië, 11029
- Werving
- Research Site
-
New Delhi, Indië, 110075
- Werving
- Research Site
-
Puducherry, Indië, 605006
- Werving
- Research Site
-
Surat, Indië, 395002
- Werving
- Research Site
-
Thiruvananthapuram, Indië, 695011
- Werving
- Research Site
-
Vadodara, Indië, 391760
- Werving
- Research Site
-
Visakhapatnam, Indië, 530053
- Ingetrokken
- Research Site
-
-
-
-
-
Bergamo, Italië, 24127
- Werving
- Research Site
-
Empoli, Italië, 50053
- Werving
- Research Site
-
Milan, Italië, 20132
- Werving
- Research Site
-
Milan, Italië, 20141
- Werving
- Research Site
-
Modena, Italië, 41124
- Ingetrokken
- Research Site
-
Naples, Italië, 80131
- Werving
- Research Site
-
Padova, Italië, 35128
- Werving
- Research Site
-
Reggio Emilia, Italië, 42123
- Werving
- Research Site
-
Roma, Italië, 00168
- Werving
- Research Site
-
Rozzano, Italië, 20089
- Werving
- Research Site
-
-
-
-
-
Akashi-shi, Japan, 673-8558
- Werving
- Research Site
-
Bunkyō City, Japan, 113-8431
- Werving
- Research Site
-
Bunkyō City, Japan, 113-8677
- Werving
- Research Site
-
Chiba, Japan, 260-8717
- Werving
- Research Site
-
Chūōku, Japan, 104-0045
- Werving
- Research Site
-
Fukuoka, Japan, 811-1395
- Werving
- Research Site
-
Fukushima, Japan, 960-1295
- Werving
- Research Site
-
Gifu, Japan, 501-1194
- Werving
- Research Site
-
Hidaka-shi, Japan, 350-1298
- Werving
- Research Site
-
Hiroshima, Japan, 734-8551
- Werving
- Research Site
-
Hiroshima, Japan, 730-8518
- Werving
- Research Site
-
Isehara-shi, Japan, 259-1193
- Werving
- Research Site
-
Kamogawa-shi, Japan, 296-8602
- Werving
- Research Site
-
Kashiwa, Japan, 277-8577
- Werving
- Research Site
-
Kitaadachi-gun, Japan, 362-0806
- Werving
- Research Site
-
Kumamoto, Japan, 860-8556
- Werving
- Research Site
-
Kurume-shi, Japan, 830-0011
- Werving
- Research Site
-
Kōtoku, Japan, 135-8550
- Werving
- Research Site
-
Matsuyama, Japan, 791-0280
- Werving
- Research Site
-
Nagoya, Japan, 466-8560
- Werving
- Research Site
-
Nagoya, Japan, 467-8602
- Werving
- Research Site
-
Niigata, Japan, 951-8566
- Werving
- Research Site
-
Nishinomiya-shi, Japan, 663-8501
- Werving
- Research Site
-
Okayama, Japan, 700-8558
- Werving
- Research Site
-
Osaka, Japan, 541-8567
- Werving
- Research Site
-
Osakasayama-shi, Japan, 589-8511
- Werving
- Research Site
-
Ota-shi, Japan, 373-8550
- Werving
- Research Site
-
Sapporo, Japan, 003-0804
- Werving
- Research Site
-
Sendai, Japan, 980-8574
- Werving
- Research Site
-
Shinagawa-ku, Japan, 142-8666
- Werving
- Research Site
-
Shinjuku-ku, Japan, 162-8655
- Werving
- Research Site
-
Shinjuku-ku, Japan, 160-0023
- Werving
- Research Site
-
Tsu, Japan, 514-8507
- Werving
- Research Site
-
Tsukuba, Japan, 305-8577
- Werving
- Research Site
-
Yokohama, Japan, 241-8515
- Werving
- Research Site
-
-
-
-
-
CD Mexico, Mexico, 04980
- Werving
- Research Site
-
Guadalajara, Mexico, 44670
- Ingetrokken
- Research Site
-
Guadalajara, Mexico, 44638
- Werving
- Research Site
-
Mexico City, Mexico, 0 3100
- Werving
- Research Site
-
Mexico City, Mexico, 06760
- Werving
- Research Site
-
México, Mexico, 04700
- Werving
- Research Site
-
Tuxtla Gutiérrez, Mexico, 29090
- Werving
- Research Site
-
-
-
-
-
Bialystok, Polen, 15-027
- Ingetrokken
- Research Site
-
Bydgoszcz, Polen, 85-796
- Ingetrokken
- Research Site
-
Gdansk, Polen, 80-952
- Werving
- Research Site
-
Gdynia, Polen, 81-519
- Ingetrokken
- Research Site
-
Konin, Polen, 62-500
- Ingetrokken
- Research Site
-
Krakow, Polen, 31-501
- Werving
- Research Site
-
Krakow, Polen, 31-115
- Ingetrokken
- Research Site
-
Legnica, Polen, 59-220
- Ingetrokken
- Research Site
-
Lodz, Polen, 90-302
- Werving
- Research Site
-
Lublin, Polen, 20-090
- Ingetrokken
- Research Site
-
Przemyśl, Polen, 37-700
- Ingetrokken
- Research Site
-
Warsaw, Polen, 02-781
- Werving
- Research Site
-
Wroclaw, Polen, 53-413
- Ingetrokken
- Research Site
-
-
-
-
-
Singapore, Singapore, 169610
- Werving
- Research Site
-
Singapore, Singapore, 308433
- Werving
- Research Site
-
Singapore, Singapore, 217562
- Werving
- Research Site
-
Singapore, Singapore, 119228
- Ingetrokken
- Research Site
-
-
-
-
-
Barcelona, Spanje, 8035
- Werving
- Research Site
-
Barcelona, Spanje, 08028
- Ingetrokken
- Research Site
-
Granada, Spanje, 18016
- Werving
- Research Site
-
Hospitalet deLlobregat, Spanje, 08907
- Werving
- Research Site
-
Madrid, Spanje, 28007
- Werving
- Research Site
-
Madrid, Spanje, 28034
- Ingetrokken
- Research Site
-
Pamplona, Spanje, 31008
- Werving
- Research Site
-
Santander, Spanje, 39008
- Werving
- Research Site
-
-
-
-
-
Hsinchu, Taiwan, 300
- Werving
- Research Site
-
Kaohsiung City, Taiwan, 80756
- Werving
- Research Site
-
Taichung, Taiwan, 40447
- Werving
- Research Site
-
Tainan, Taiwan, 704
- Werving
- Research Site
-
Taipei, Taiwan, 100
- Werving
- Research Site
-
Taipei, Taiwan, 112
- Werving
- Research Site
-
Taipei, Taiwan, 10449
- Werving
- Research Site
-
Taipei, Taiwan, 11259
- Werving
- Research Site
-
Taoyuan, Taiwan, 333
- Werving
- Research Site
-
-
-
-
-
Bangkok, Thailand, 10210
- Werving
- Research Site
-
Bangkok, Thailand, 10400
- Werving
- Research Site
-
Bangkok, Thailand, 10330
- Werving
- Research Site
-
Bangkok, Thailand, 10700
- Werving
- Research Site
-
Chiang Mai, Thailand, 50200
- Werving
- Research Site
-
Dusit, Thailand, 10300
- Werving
- Research Site
-
Khon Kaen, Thailand, 40002
- Werving
- Research Site
-
Songkhla, Thailand, 90110
- Werving
- Research Site
-
-
-
-
-
Ankara, Turkije (Türkiye), 6200
- Werving
- Research Site
-
Ankara, Turkije (Türkiye), 06520
- Werving
- Research Site
-
Besevler Ankara, Turkije (Türkiye)
- Werving
- Research Site
-
Istanbul, Turkije (Türkiye), 34010
- Werving
- Research Site
-
Izmir, Turkije (Türkiye), 35575
- Ingetrokken
- Research Site
-
Küçükçekmece, Turkije (Türkiye), 34295
- Werving
- Research Site
-
Samsun, Turkije (Türkiye), 55200
- Werving
- Research Site
-
-
-
-
-
Cardiff, Verenigd Koninkrijk, CF14 2TL
- Werving
- Research Site
-
Chelsea, Verenigd Koninkrijk, SW3 6JJ
- Werving
- Research Site
-
Leicester, Verenigd Koninkrijk, Le5 4PW
- Werving
- Research Site
-
Liverpool, Verenigd Koninkrijk, L7 8YA
- Beëindigd
- Research Site
-
London, Verenigd Koninkrijk, EC1A 7BE
- Werving
- Research Site
-
London, Verenigd Koninkrijk, SW17 0QT
- Ingetrokken
- Research Site
-
Oxford, Verenigd Koninkrijk, OX3 7LE
- Geschorst
- Research Site
-
Surrey, Verenigd Koninkrijk, GU2 7XX
- Geschorst
- Research Site
-
Sutton, Verenigd Koninkrijk, SM2 5PT
- Werving
- Research Site
-
Taunton, Verenigd Koninkrijk, TA1 5DA
- Werving
- Research Site
-
-
-
-
Alabama
-
Daphne, Alabama, Verenigde Staten, 36526
- Werving
- Research Site
-
-
Arkansas
-
Springdale, Arkansas, Verenigde Staten, 72762
- Werving
- Research Site
-
-
California
-
Duarte, California, Verenigde Staten, 91010
- Ingetrokken
- Research Site
-
Fountain Valley, California, Verenigde Staten, 92708
- Nog niet aan het werven
- Research Site
-
Glendale, California, Verenigde Staten, 91204
- Werving
- Research Site
-
Sacramento, California, Verenigde Staten, 95817
- Werving
- Research Site
-
Santa Rosa, California, Verenigde Staten, 95403
- Ingetrokken
- Research Site
-
-
Colorado
-
Aurora, Colorado, Verenigde Staten, 80012
- Werving
- Research Site
-
Denver, Colorado, Verenigde Staten, 80210
- Nog niet aan het werven
- Research Site
-
-
Connecticut
-
New Haven, Connecticut, Verenigde Staten, 06510
- Werving
- Research Site
-
-
Florida
-
Altamonte Springs, Florida, Verenigde Staten, 32701
- Nog niet aan het werven
- Research Site
-
Jacksonville, Florida, Verenigde Staten, 32256
- Ingetrokken
- Research Site
-
Miami, Florida, Verenigde Staten, 33176
- Werving
- Research Site
-
Palm Bay, Florida, Verenigde Staten, 32909
- Ingetrokken
- Research Site
-
Plantation, Florida, Verenigde Staten, 33324
- Werving
- Research Site
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten, 30318
- Geschorst
- Research Site
-
-
Hawaii
-
Honolulu, Hawaii, Verenigde Staten, 96819
- Ingetrokken
- Research Site
-
-
Illinois
-
Chicago, Illinois, Verenigde Staten, 60637
- Werving
- Research Site
-
Decatur, Illinois, Verenigde Staten, 62526
- Ingetrokken
- Research Site
-
Elmhurst, Illinois, Verenigde Staten, 60126
- Ingetrokken
- Research Site
-
Naperville, Illinois, Verenigde Staten, 60540
- Ingetrokken
- Research Site
-
-
Indiana
-
New Albany, Indiana, Verenigde Staten, 47150
- Ingetrokken
- Research Site
-
-
Iowa
-
Des Moines, Iowa, Verenigde Staten, 50309
- Werving
- Research Site
-
-
Kentucky
-
Lexington, Kentucky, Verenigde Staten, 40503
- Ingetrokken
- Research Site
-
Louisville, Kentucky, Verenigde Staten, 40202
- Ingetrokken
- Research Site
-
Louisville, Kentucky, Verenigde Staten, 40207
- Ingetrokken
- Research Site
-
-
Louisiana
-
Baton Rouge, Louisiana, Verenigde Staten, 70809
- Werving
- Research Site
-
Baton Rouge, Louisiana, Verenigde Staten, 70808
- Ingetrokken
- Research Site
-
-
Maryland
-
Baltimore, Maryland, Verenigde Staten, 21215
- Ingetrokken
- Research Site
-
Columbia, Maryland, Verenigde Staten, 21044
- Werving
- Research Site
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02111
- Ingetrokken
- Research Site
-
Worcester, Massachusetts, Verenigde Staten, 01655
- Ingetrokken
- Research Site
-
-
Michigan
-
Detroit, Michigan, Verenigde Staten, 48201
- Werving
- Research Site
-
Grand Rapids, Michigan, Verenigde Staten, 49503
- Ingetrokken
- Research Site
-
-
Minnesota
-
Saint Paul, Minnesota, Verenigde Staten, 55109
- Werving
- Research Site
-
-
Mississippi
-
Hattiesburg, Mississippi, Verenigde Staten, 39401
- Ingetrokken
- Research Site
-
-
Missouri
-
St Louis, Missouri, Verenigde Staten, 63129
- Werving
- Research Site
-
-
New Mexico
-
Albuquerque, New Mexico, Verenigde Staten, 87109
- Werving
- Research Site
-
-
New York
-
Albany, New York, Verenigde Staten, 12206
- Ingetrokken
- Research Site
-
New York, New York, Verenigde Staten, 10065
- Werving
- Research Site
-
Stony Brook, New York, Verenigde Staten, 11794-7263
- Werving
- Research Site
-
-
Ohio
-
Cincinnati, Ohio, Verenigde Staten, 45219
- Werving
- Research Site
-
Cincinnati, Ohio, Verenigde Staten, 45245
- Werving
- Research Site
-
Cleveland, Ohio, Verenigde Staten, 44195
- Werving
- Research Site
-
-
Pennsylvania
-
York, Pennsylvania, Verenigde Staten, 17403
- Ingetrokken
- Research Site
-
-
Rhode Island
-
Providence, Rhode Island, Verenigde Staten, 02903
- Werving
- Research Site
-
-
Tennessee
-
Chattanooga, Tennessee, Verenigde Staten, 37404
- Werving
- Research Site
-
Nashville, Tennessee, Verenigde Staten, 37203
- Werving
- Research Site
-
-
Texas
-
Dallas, Texas, Verenigde Staten, 75246
- Werving
- Research Site
-
Dallas, Texas, Verenigde Staten, 75230
- Ingetrokken
- Research Site
-
Dallas, Texas, Verenigde Staten, 75246
- Ingetrokken
- Research Site
-
El Paso, Texas, Verenigde Staten, 79902
- Werving
- Research Site
-
Flower Mound, Texas, Verenigde Staten, 75028
- Ingetrokken
- Research Site
-
Fort Worth, Texas, Verenigde Staten, 76104
- Ingetrokken
- Research Site
-
Houston, Texas, Verenigde Staten, 77054
- Ingetrokken
- Research Site
-
Houston, Texas, Verenigde Staten, 77090
- Ingetrokken
- Research Site
-
Houston, Texas, Verenigde Staten, 77098
- Ingetrokken
- Research Site
-
Kingwood, Texas, Verenigde Staten, 77339
- Ingetrokken
- Research Site
-
McKinney, Texas, Verenigde Staten, 75071
- Ingetrokken
- Research Site
-
Sugar Land, Texas, Verenigde Staten, 77479
- Werving
- Research Site
-
-
Virginia
-
Charlottesville, Virginia, Verenigde Staten, 22903
- Werving
- Research Site
-
Fairfax, Virginia, Verenigde Staten, 22031
- Werving
- Research Site
-
Midlothian, Virginia, Verenigde Staten, 23114
- Werving
- Research Site
-
Norfolk, Virginia, Verenigde Staten, 23502
- Werving
- Research Site
-
Roanoke, Virginia, Verenigde Staten, 24014
- Werving
- Research Site
-
-
Washington
-
Tacoma, Washington, Verenigde Staten, 98405
- Werving
- Research Site
-
-
Wisconsin
-
Madison, Wisconsin, Verenigde Staten, 53792
- Ingetrokken
- Research Site
-
-
-
-
-
Da Nang, Vietnam, 550000
- Werving
- Research Site
-
Hanoi, Vietnam, 100000
- Werving
- Research Site
-
Ho Chi Minh City, Vietnam, 700000
- Werving
- Research Site
-
Huế, Vietnam, 530000
- Werving
- Research Site
-
Hồ Chí Minh, Vietnam, 700000
- Werving
- Research Site
-
Viet Tri, Vietnam, 35000
- Werving
- Research Site
-
Vinh, Vietnam, 460000
- Werving
- Research Site
-
-
-
-
-
Busan, Zuid -Korea, 49241
- Voltooid
- Research Site
-
Daegu, Zuid -Korea, 41404
- Werving
- Research Site
-
Goyang-si, Zuid -Korea, 10408
- Werving
- Research Site
-
Seongnam-si, Zuid -Korea, 13620
- Werving
- Research Site
-
Seoul, Zuid -Korea, 03080
- Werving
- Research Site
-
Seoul, Zuid -Korea, 06351
- Werving
- Research Site
-
Seoul, Zuid -Korea, 05505
- Werving
- Research Site
-
Seoul, Zuid -Korea, 03722
- Werving
- Research Site
-
Seoul, Zuid -Korea, 06591
- Werving
- Research Site
-
Seoul, Zuid -Korea, 02841
- Werving
- Research Site
-
Seoul, Zuid -Korea, 06273
- Werving
- Research Site
-
-
-
-
-
Cape Town, Zuid-Afrika, 7570
- Werving
- Research Site
-
Johannesburg, Zuid-Afrika, 2013
- Werving
- Research Site
-
Johannesburg, Zuid-Afrika, 2196
- Werving
- Research Site
-
Johannesburg, Zuid-Afrika, 2193
- Werving
- Research Site
-
Paarl, Zuid-Afrika, 7646
- Werving
- Research Site
-
Pretoria, Zuid-Afrika, 0081
- Werving
- Research Site
-
Pretoria, Zuid-Afrika, 0081
- Voltooid
- Research Site
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Key Inclusion Criteria
-
Histologically or cytologically documented locally recurrent inoperable, which cannot be treated with curative intent, or metastatic TNBC, as defined by the ASCO-CAP guidelines.
-
ECOG PS 0 or 1.
-
Participants are expected to provide an FFPE tumour sample collected from a locally recurrent inoperable or metastatic tumour. Alternatively, an archival FFPE tumour sample can be submitted; it must have been collected ≤ 3 years prior to the participant signing informed consent (screening start).
-
PD-L1 positive TNBC based on results from an appropriately validated investigational PD-L1 (22C3) assay (CPS ≥ 10) from a sponsor designated central laboratory.
-
No prior chemotherapy or other systemic anti-cancer therapy for metastatic or locally recurrent inoperable breast cancer.
- Patients with recurrent disease will be eligible if they have completed treatment for Stage I-III breast cancer, if indicated, and ≥6 months have elapsed between completion of treatment with curative intent and the first documented recurrence.
-
Eligible for one of the chemotherapy options listed as ICC (paclitaxel, nab-paclitaxel, or gemcitabine + carboplatin).
-
Measurable disease as per RECIST 1.1.
-
Adequate bone marrow reserve and organ function.
-
Male and female participants of childbearing potential must agree to use protocol-specified method(s) of contraception.
Key Exclusion Criteria
-
As judged by investigator, any evidence of diseases (such as severe or uncontrolled medical conditions including systemic diseases, uncontrolled hypertension, serious gastrointestinal conditions associated with diarrhoea, chronic diverticulitis or previous complicated diverticulitis, history of allogeneic organ transplant, and active bleeding diseases, ongoing and active infection, significant cardiac conditions, substance abuse, psychiatric illness/social situation or psychological conditions) which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardize compliance with the protocol.
-
History of another primary malignancy except for malignancy treated with curative intent with no known active disease within 2 years before Cycle 1 Day 1 and of low potential risk for recurrence.
-
Participants with a history of previously treated neoplastic spinal cord compression or treated, clinically inactive brain metastases that are no longer symptomatic, who require no treatment with corticosteroids or anticonvulsants, may be included in the study if they have recovered from acute toxic effects of radiotherapy.
- Participants with treated clinically inactive brain metastases that are no longer symptomatic, who require no treatment with corticosteroids or anticonvulsants, may be included in the study if they have recovered from acute toxic effects of radiotherapy.
-
Uncontrolled infection requiring IV antibiotics, antivirals or antifungals.
-
Active or uncontrolled hepatitis B or C virus infection.
-
Known HIV infection that is not well controlled.
-
Uncontrolled or significant cardiac disease.
-
History of non-infectious ILD/pneumonitis (including radiation pneumonitis) that required steroids, current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.
-
Clinically severe pulmonary function compromise.
-
Clinically significant corneal disease.
-
Active or prior documented autoimmune or inflammatory disorders.
-
Prior exposure to any treatment including ADC containing a chemotherapeutic agent targeting topoisomerase I and TROP2-targeted therapy.
-
Any concurrent anti-cancer treatment.
-
Participants with a known severe hypersensitivity to PD-1/PD-L1 inhibitors or Dato-DXd.
-
Currently pregnant (confirmed with positive pregnancy test), breastfeeding or planning to become pregnant.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Dato-DXd + durvalumab
Arm 1: Dato-DXd + durvalumab |
Provided in 100mg vials. IV infusion. Experimental drug.
Andere namen:
Provided in 500mg vials. IV infusion. Experimental drug.
Andere namen:
|
|
Actieve vergelijker: Investigator's Choice of Chemotherapy (ICC) in combination with pembrolizumab
Arm 2: Investigator's Choice of Chemotherapy (ICC) in combination with pembrolizumab (paclitaxel, nab-paclitaxel, or gemcitabine + carboplatin) |
IV infusion. Active comparator. IV infusion. Active comparator. IV infusion. Active comparator. IV infusion. Active comparator. IV infusion. Active comparator. |
|
Experimenteel: Dato-DXd
Arm 3: Dato-DXd |
Provided in 100mg vials. IV infusion. Experimental drug.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Progression Free Survival (PFS)
Tijdsspanne: From randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause (anticipated to be up to 33 months).
|
PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause. The comparison will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy, receives another anticancer therapy or clinically progresses prior to RECIST 1.1 progression. However, if the participant progresses or dies immediately after 2 or more consecutive missed visits, the participant will be censored at the time of the latest evaluable assessment prior to the 2 missed visits. The measure of interest is the HR of PFS. |
From randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause (anticipated to be up to 33 months).
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Overall Survival (OS)
Tijdsspanne: From randomisation until the date of death due to any cause (anticipated to be up to 64 months).
|
OS is defined as the time from randomisation until the date of death due to any cause. |
From randomisation until the date of death due to any cause (anticipated to be up to 64 months).
|
|
Objective Response Rate (ORR)
Tijdsspanne: From randomisation up until progression (anticipated to be up to 33 months).
|
ORR is defined as the proportion of participants who have a CR or PR, as determined by the BICR/investigator assessment, per RECIST 1.1. |
From randomisation up until progression (anticipated to be up to 33 months).
|
|
Duration of Response (DoR)
Tijdsspanne: From the date of first documented response until date of documented progression per RECIST 1.1, as assessed by BICR/investigator assessment or death due to any cause (anticipated to be up to 33 months).
|
DoR is defined as the time from the date of first documented response until date of documented progression per RECIST 1.1, as assessed by BICR/investigator assessment or death due to any cause. |
From the date of first documented response until date of documented progression per RECIST 1.1, as assessed by BICR/investigator assessment or death due to any cause (anticipated to be up to 33 months).
|
|
Progression-Free Survival (PFS) by Investigator assessment
Tijdsspanne: From randomisation until progression per RECIST 1.1 as assessed by the investigator, or death due to any cause (anticipated to be up to 33 months).
|
PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by investigator, or death due to any cause. |
From randomisation until progression per RECIST 1.1 as assessed by the investigator, or death due to any cause (anticipated to be up to 33 months).
|
|
Clinical Benefit Rate (CBR) at 24 weeks
Tijdsspanne: From randomisation up until progression, or the last evaluable assessment in the absence of progression (anticipated to be up to 33 months).
|
CBR at 24 weeks is defined as the percentage of participants who have a CR or PR or who have SD, per RECIST 1.1, as assessed by BICR/per investigator assessment and derived from the raw tumour data for at least 23 weeks after randomisation. |
From randomisation up until progression, or the last evaluable assessment in the absence of progression (anticipated to be up to 33 months).
|
|
Time to deterioration (TTD) in breast and arm symptoms in participants treated with Dato-DXd + durvalumab compared with ICC + pembrolizumab
Tijdsspanne: From the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).
|
TTD in breast symptoms and arm symptoms as measured by the arm symptoms scale from EORTC IL116 TTD is defined as time from the date of randomisation to the date of deterioration. Deterioration is defined as change from baseline that reaches a clinically meaningful deterioration threshold. |
From the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).
|
|
Time to deterioration (TTD) in pain in participants treated with Dato-DXd + durvalumab compared with ICC + pembrolizumab
Tijdsspanne: Time from the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).
|
TTD in pain as measured by the EORTC IL199. |
Time from the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).
|
|
Time to deterioration (TTD) in physical functioning in participants treated with Dato-DXd + durvalumab compared with ICC + pembrolizumab
Tijdsspanne: From the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).
|
TTD in physical function as measured by the PROMIS Short Form v2.0 - Physical Function 8c. |
From the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).
|
|
Time to deterioration (TTD) in GHS/QoL in participants treated with Dato-DXd + durvalumab compared with ICC + pembrolizumab
Tijdsspanne: From the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).
|
TTD in GHS/QoL as measured by the GHS/QoL scale from EORTC IL172. |
From the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).
|
|
Time to First Subsequent Therapy (TFST)
Tijdsspanne: From randomisation until the start date of the first subsequent anticancer therapy after discontinuation of randomised treatment, or death due to any cause (anticipated to be up to 64 months).
|
TFST is defined as the time from randomisation until the start date of the first subsequent anticancer therapy after discontinuation of randomised treatment, or death due to any cause. |
From randomisation until the start date of the first subsequent anticancer therapy after discontinuation of randomised treatment, or death due to any cause (anticipated to be up to 64 months).
|
|
Time to Second Subsequent Therapy (TSST)
Tijdsspanne: From randomisation until the start date of the second subsequent anti cancer therapy after discontinuation of first subsequent treatment, or death due to any cause (anticipated to be up to 64 months).
|
TSST is defined as the time from randomisation until the start date of the second subsequent anticancer therapy after discontinuation of first subsequent treatment, or death due to any cause. |
From randomisation until the start date of the second subsequent anti cancer therapy after discontinuation of first subsequent treatment, or death due to any cause (anticipated to be up to 64 months).
|
|
Progression Free Survival 2 (PFS2)
Tijdsspanne: From the randomisation to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy, or death (anticipated to be up to 64 months).
|
PFS2 will be defined as the time from the randomisation to the earliest progression event (following the initial progression), subsequent to first subsequent therapy, or death. The date of second progression will be recorded by the investigator in the eCRF and defined according to local standard clinical practice based on radiological or clinical progression. |
From the randomisation to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy, or death (anticipated to be up to 64 months).
|
|
Pharmacokinetics of Dato-DXd in combination with durvalumab
Tijdsspanne: From first dose to end of treatment (anticipated to be up to 33 months).
|
Concentration of Dato-DXd, total anti-TROP2 antibody, and DXd (payload) in plasma. |
From first dose to end of treatment (anticipated to be up to 33 months).
|
|
Immunogenicity of Dato-DXd in combination with durvalumab
Tijdsspanne: From first dose to end of treatment safety follow-up (anticipated to be up to 33 months).
|
Presence of antidrug antibodies for Dato-DXd (confirmatory results: positive or negative, titres). |
From first dose to end of treatment safety follow-up (anticipated to be up to 33 months).
|
|
Safety and tolerability of Dato-DXd + durvalumab as compared with ICC + pembrolizumab
Tijdsspanne: From first dose to end of treatment safety follow-up (anticipated to be up to 33 months).
|
Safety and tolerability will be evaluated in the safety population in terms of AEs. |
From first dose to end of treatment safety follow-up (anticipated to be up to 33 months).
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Publicaties en nuttige links
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Pathologische processen
- Neoplasmata per site
- Neoplasmata
- Neoplastische processen
- Huidziektes
- Borst ziekten
- Pathologische aandoeningen, tekenen en symptomen
- Huid- en bindweefselaandoeningen
- Borstneoplasmata
- Neoplasma metastase
- Organische chemicaliën
- Heterocyclische verbindingen, 1-ring
- Heterocyclische verbindingen
- Koolwaterstoffen
- Cycloparaffins
- Koolwaterstoffen, alicyclisch
- Koolwaterstoffen, cyclisch
- Terpenen
- Coördinatiecomplexen
- Taxoids
- Cyclodecanes
- Diterpenen
- Deoxycytidine
- Cytidine
- Pyrimidine -nucleosiden
- Pyrimidines
- Gemcitabine
- Carboplatine
- Paclitaxel
- pembrolizumab
- durvalumab
- 130-nm albumine-gebonden Paclitaxel
Andere studie-ID-nummers
- D7630C00001
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
IPD-tijdsbestek voor delen
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD-toegangscriteria voor delen
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .